The Conquer Cancer Foundation of ASCO Resident Travel Award for Underrepresented Populations (RTA) is designed to facilitate the recruitment and retention of individuals from underrepresented populations in medicine to cancer careers and increase access to quality care for underserved communities. This program was initially developed as part of the Conquer Cancer Foundation/ASCO/Susan G. Komen for the Cure® Quality of Care Initiative.
The Resident Travel Award for Underrepresented Populations provides financial support for residents from underrepresented populations to attend ASCO’s Annual Meeting. The intention of this award is to attract residents from underrepresented populations to a possible career in one of the oncology specialties. This travel award will allow the recipients to travel to the ASCO Annual Scientific Meeting, where they will have an opportunity to meet oncologists and to understand the career possibilities in this area. The Resident Travel Award for Underrepresented Populations includes a $1,500 travel advance, complimentary Annual Meeting registration, and access to the Annual Meeting housing block and ASCO’s travel agent.
To qualify for the Resident Travel Award, applicants must be enrolled in an ACGME-accredited residency program required for future training in a cancer related subspecialty (i.e. Internal Medicine considering Med/Onc, Surgery considering Surg/Onc) and be of an underrepresented population as defined by the program eligibility criteria. Candidates must be U.S. citizens, U.S. nationals or permanent residents. Candidates must demonstrate an interest in pursuing oncology as a career as well as a record of good academic standing.
Learn how receiving the Resident Travel Award for Underrepresented Populations encouraged 2009 RTA recipient Dr. Derrick Cox to pursue a career in oncology and how this award has had a direct impact on his current success as an oncologist.
The 2014 RTA application is now closed. For more information, please read the most recent 2014 Request for Proposals.
The 2014 RTAs are supported by:
|Janssen Biotech, Inc.|